Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Salirasib

EU orphan designation number: EU/3/11/871   
Active ingredient: Salirasib
Indication: Treatment of pancreatic cancer
Sponsor: Kadmon International Ltd.
4th floor, Haines House, 21 John Street, London WC1N 2BP, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
24/06/2011 Centralised Orphan - Designation EMA/OD/150/10 (2011)4545 of 21/06/2011
06/11/2012 Centralised Orphan - Transfer of orphan designation EMA/OD/150/10/T/01 (2012)7995 of 31/10/2012